PHARMA Stock Overview An investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Pharmaniaga Berhad Competitors Price History & Performance
Summary of share price highs, lows and changes for Pharmaniaga Berhad Historical stock prices Current Share Price RM 0.35 52 Week High RM 0.47 52 Week Low RM 0.29 Beta 1.46 1 Month Change -1.39% 3 Month Change -8.97% 1 Year Change -6.58% 3 Year Change -50.69% 5 Year Change -15.07% Change since IPO 206.83%
Recent News & Updates
New major risk - Financial position Nov 27
Third quarter 2024 earnings released: EPS: RM0.07 (vs RM0.037 loss in 3Q 2023) Nov 27
Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024 Aug 30
Second quarter 2024 earnings released Aug 22
High number of new directors Aug 01
New minor risk - Share price stability Jul 24 See more updates
New major risk - Financial position Nov 27
Third quarter 2024 earnings released: EPS: RM0.07 (vs RM0.037 loss in 3Q 2023) Nov 27
Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024 Aug 30
Second quarter 2024 earnings released Aug 22
High number of new directors Aug 01
New minor risk - Share price stability Jul 24
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry Jul 18
Now 20% overvalued after recent price rise Jul 17
First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023) May 28
Now 24% undervalued after recent price drop May 28
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S May 09
Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024 May 01
High number of new directors Apr 01 Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee
Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer Mar 08
New major risk - Revenue and earnings growth Mar 01
Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022) Mar 01
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024 Mar 01 Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024
Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director Feb 19
New minor risk - Share price stability Dec 01
Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022) Nov 30
Price target decreased by 19% to RM0.28 Oct 13
High number of new and inexperienced directors Sep 01
Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022) Aug 12 Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee
New minor risk - Shareholder dilution Jul 23
New minor risk - Market cap size Jun 24 Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding Jun 16
Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee
First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022) May 19
Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director May 09
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate Apr 19
Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021) Feb 28
Price target decreased by 33% to RM0.41 Feb 28 Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee
Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021) Nov 25
Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023 Nov 24
High number of new directors Nov 16
Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd. Nov 01
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price Oct 03
Consensus EPS estimates fall by 13% Aug 26
Price target decreased to RM0.75 Aug 22
Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021) Aug 20
Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022 Aug 19 Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee
Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director Jul 21
Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director Jul 20
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation? Jul 19
Price target decreased to RM0.87 May 23
Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022 May 21
Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee May 14
Full year 2021 earnings: EPS and revenues exceed analyst expectations May 04
Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022 May 02
High number of new and inexperienced directors Apr 27
Upcoming dividend of RM0.05 per share Feb 28
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)? Feb 18
Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022 Feb 18
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 18 Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital Dec 10
Consensus EPS estimates increase to RM0.09 Dec 07
Upcoming dividend of RM0.02 per share Nov 29
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts Nov 24
Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020) Nov 21
Upcoming dividend of RM0.015 per share Aug 31
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings Aug 27
Independent Non-Executive Director Zainal Shariff has left the company Aug 27
Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020) Aug 22 Shareholder Returns PHARMA MY Healthcare MY Market 7D -2.7% -1.2% -1.0% 1Y -6.6% 20.2% 10.0%
See full shareholder returns
Return vs Market: PHARMA underperformed the MY Market which returned 10% over the past year.
Price Volatility Is PHARMA's price volatile compared to industry and market? PHARMA volatility PHARMA Average Weekly Movement 5.9% Healthcare Industry Average Movement 3.9% Market Average Movement 4.8% 10% most volatile stocks in MY Market 10.5% 10% least volatile stocks in MY Market 2.5%
Stable Share Price: PHARMA has not had significant price volatility in the past 3 months compared to the MY market.
Volatility Over Time: PHARMA's weekly volatility (6%) has been stable over the past year.
About the Company Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through three segments: Logistics and Distribution, Manufacturing, and Indonesia. It is involved in manufacturing, distribution, trading, wholesaling, and marketing pharmaceutical and medical products; supply, trading, and installation of medical and hospital equipment; and trading and wholesaling of consumer products.
Show more Pharmaniaga Berhad Fundamentals Summary How do Pharmaniaga Berhad's earnings and revenue compare to its market cap? PHARMA fundamental statistics Market cap RM 511.64m Earnings (TTM ) RM 94.05m Revenue (TTM ) RM 3.62b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PHARMA income statement (TTM ) Revenue RM 3.62b Cost of Revenue RM 3.18b Gross Profit RM 440.76m Other Expenses RM 346.72m Earnings RM 94.05m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.065 Gross Margin 12.17% Net Profit Margin 2.60% Debt/Equity Ratio -820.8%
How did PHARMA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 23:09 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hsien Jin Lam CGS International Yee Low Hong Leong Investment Bank Berhad Ping-Khoon Choo Kenanga Research
Show 1 more analysts 
